Characterization of human iPSC-derived endothelial cells in a vascularized microphysiological system

Abstract The discovery of induced pluripotent stem cells (iPSC) was met with optimism that this new technology would revolutionize how we model and treat human diseases. The last 20 years of research, however, has somewhat tempered the initial enthusiasm as the technology is often challenging to adopt for a given application. Here we outline a methodology for using iPSC in tissue modeling by combining the environment of a microphysiological system (MPS) platform, the vascularized micro organ (VMO), with more nuanced differentiation techniques to create microvessels using iPSC-derived endothelial cells (iEC) suitable for long-term in vitro tissue studies. We describe the impact of optimized differentiation conditions on iEC beyond selection tools usually sufficient for identifying functional primary EC and offer key metrics for the unique characterization and evaluation of the vasculogenic potential of these iEC. Instead of relying solely on expression of key EC identity genes such as CD31 and VWF to assume differentiation efficiency, we propose a novel screening panel to predict the functional capacity of iEC. In vasculogenic EC we consistently observed expression of eight genes ( TPM1 , IARS1 , SPARC , PTPN13 , NOTCH2 , TTC3 , CNN2 and CBX5 ) while low or absent expression of a further eight genes ( ID3 , CALCRL , WWTR1 , ERG , MYCT1 , DUSP6 , FZD4 and STAB1 ) clearly predicted poor vasculogenic potential. These innovations and robust characterization will help to identify iEC that can be used in the generation of novel vascularized disease platforms that capture patient genetic variability and/or replicate in situ gene expression of genetic disorders.

Authors

Institutions

Publication Details

Journal
Stem Cell Research & Therapy
Published
2026-11-17
DOI
https://doi.org/10.1186/s13287-026-05401-x
Primary Topic
Pluripotent Stem Cells Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Characterization of human iPSC-derived endothelial cells in a vascularized microphysiological system

Yu‐Hsi Chen, Benjamen T. O’Donnell, Vanessa Bröker, Makena L. Ewald et al.
Stem Cell Research & Therapy
Pluripotent Stem Cells Research
article

Characterization of human iPSC-derived endothelial cells in a vascularized microphysiological system

Yu‐Hsi Chen, Benjamen T. O’Donnell, Vanessa Bröker, Makena L. Ewald, Christopher J. Hatch, William K. Van Trigt, Christopher C.W. Hughes, Celeste N Sanchez, Erin E. Sanchez, Zee S. Piermatteo, Caleb A. Smeraldi, Jennifer S. Fang
article en

Abstract

Abstract The discovery of induced pluripotent stem cells (iPSC) was met with optimism that this new technology would revolutionize how we model and treat human diseases. The last 20 years of research, however, has somewhat tempered the initial enthusiasm as the technology is often challenging to adopt for a given application. Here we outline a methodology for using iPSC in tissue modeling by combining the environment of a microphysiological system (MPS) platform, the vascularized micro organ (VMO), with more nuanced differentiation techniques to create microvessels using iPSC-derived endothelial cells (iEC) suitable for long-term in vitro tissue studies. We describe the impact of optimized differentiation conditions on iEC beyond selection tools usually sufficient for identifying functional primary EC and offer key metrics for the unique characterization and evaluation of the vasculogenic potential of these iEC. Instead of relying solely on expression of key EC identity genes such as CD31 and VWF to assume differentiation efficiency, we propose a novel screening panel to predict the functional capacity of iEC. In vasculogenic EC we consistently observed expression of eight genes ( TPM1 , IARS1 , SPARC , PTPN13 , NOTCH2 , TTC3 , CNN2 and CBX5 ) while low or absent expression of a further eight genes ( ID3 , CALCRL , WWTR1 , ERG , MYCT1 , DUSP6 , FZD4 and STAB1 ) clearly predicted poor vasculogenic potential. These innovations and robust characterization will help to identify iEC that can be used in the generation of novel vascularized disease platforms that capture patient genetic variability and/or replicate in situ gene expression of genetic disorders.

Stem Cell Research & Therapy
Tulane University (US), University of California, Irvine (US)
National Heart, Lung, and Blood Institute, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences
Good health and well-being
Pluripotent Stem Cells Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon